The latest research waiting for you

Here you find Research our Clients trust us with allocating to the best research sites globally.
To participate, please request password at

Phase I

YND-H-01 in Hematologic Malignancies

This is a Phase 1 dose-escalation study of a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of specific CDK9 Inh.
Read more